Marker Therapeutics secured a $2.6 million FDA grant to fund a Phase 1 trial of its lead therapy MT-601, representing financial validation for its long-running pancreatic cancer clinical program.
Marker Therapeutics secured a $2.6 million FDA grant to fund a Phase 1 trial of its lead therapy MT-601, representing financial validation for its long-running pancreatic cancer clinical program.